Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer
Level 5 - mechanism / opinion, no new human data
Narrative review with mechanism-based reasoning and no primary human data
OpenAlex W3204655553 · doi:10.1186/s12943-021-01431-6
What was done
This narrative review summarizes the mechanism and development of the CRISPR/Cas9 gene editing platform and surveys its applications across basic cancer research, oncology diagnostics, and cancer therapy, alongside emerging research trends and future challenges.
What was found
The abstract reports no numerical findings or primary data; it qualitatively states that CRISPR/Cas9 enables targeted locus-specific genomic edits to investigate tumorigenesis mechanisms and is increasingly applied to oncology research and therapeutics.
Why it matters
It provides a broad overview of how RNA-guided CRISPR/Cas9 tools are integrated into cancer modeling, biomarker detection, and therapeutic development.
Limits
As a narrative review, it lacks a systematic search protocol or quantitative data synthesis. The abstract contains no primary human, animal, or bench experimental measurements.
Cited by
- supports Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize for discovering that CRISPR can be repurposed for targeted DNA cutting.